endpts.com·May 1, 2026
Shao-Lee Lin, the founder of Acelyrin, has been appointed as the new CEO of Cue Biopharma, which is undergoing a transformation that includes licensing a new allergy treatment developed in Taiwan.
Shao-Lee Lin's appointment as CEO of Cue Biopharma, alongside the company's licensing of a new allergy asset from Taiwan, highlights a strategic move to leverage international partnerships for innovative biotech developments. For a professional tracking healthtech and biotech, this suggests a growing trend of cross-border licensing, particularly involving Asian markets, which could present new opportunities for investment and collaboration in the biotech sector.